We develop transformative antibody therapeutics for patients, with a current focus on oncology, inflammatory diseases, and immunology.
We match disease biology and therapeutic targets with next-generation antibody formats and design challenges into blueprints for safer and more effective medicines.
Advancing a pipeline of therapeutics towards the clinic
Modality
Therapeutic area
Design Goal
Stage of Preclinical Development
Owner
Design Goal
Internalization
Therapeutic area
Oncology
Modality
ADC
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Design Goal
Dual-targeting
Therapeutic area
Sickle cell disease
Modality
IgG
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Design Goal
Avidity
Therapeutic area
Oncology
Modality
TCE
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Design Goal
AND-gated
Therapeutic area
Oncology
Modality
TCE
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Design Goal
Avidity
Therapeutic area
Oncology
Modality
TCE
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Design Goal
AND-gated
Therapeutic area
Oncology
Modality
TCE
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Design Goal
NOT-gated
Therapeutic area
Oncology
Modality
TCE
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Design Goal
Affinity, Selectivity, Formulation
Therapeutic area
I&I
Modality
TCE
Stage of development
Discovery
Lead Op
Candidate Selection
IND-enabling
Not Disclosed
Multiple Targets
Partner Programs
BigHat Biosciences collaborates with a diverse set of pharma partners to develop transformative therapeutics for patients.
PARTNER
Partner with us
BigHat engages with strategic partners to tackle complex protein therapeutic design challenges.
